These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24518527)

  • 1. Carfilzomib-related acute kidney injury.
    Jhaveri KD; Chidella S; Varghese J; Mailloux L; Devoe C
    Clin Adv Hematol Oncol; 2013; 11(9):604-5. PubMed ID: 24518527
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of multiple myeloma with carfilzomib in patients with renal injury.
    Kwon D; Niesvizky R
    Clin Adv Hematol Oncol; 2013; 11(9):605-6. PubMed ID: 24518528
    [No Abstract]   [Full Text] [Related]  

  • 3. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine.
    Wanchoo R; Khan S; Kolitz JE; Jhaveri KD
    J Oncol Pharm Pract; 2015 Aug; 21(4):313-6. PubMed ID: 24748581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.
    Ball S; Behera TR; Anwer F; Chakraborty R
    Ann Hematol; 2020 Jun; 99(6):1265-1271. PubMed ID: 32382772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.
    Atrash S; Tullos A; Panozzo S; Bhutani M; Van Rhee F; Barlogie B; Usmani SZ
    Blood Cancer J; 2015 Jan; 5(1):e272. PubMed ID: 25594159
    [No Abstract]   [Full Text] [Related]  

  • 6. Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.
    Djebbari F; Hubenov H; Neelakantan P; Wolf J; Offer M; Khera A; Louka E; Vallance G; Kothari J; Moore S; Ramasamy K
    Br J Haematol; 2020 Feb; 188(4):e57-e60. PubMed ID: 31792927
    [No Abstract]   [Full Text] [Related]  

  • 7. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
    Tjionas H; Gupta AK
    J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of acute liver failure due to carfilzomib in multiple myeloma.
    Kathi PR; Tama M; Kundumadam S; Naylor P; Mutchnick M
    J Clin Pharm Ther; 2018 Dec; 43(6):918-920. PubMed ID: 29969517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib (Kryprolis) for multiple myeloma.
    Med Lett Drugs Ther; 2012 Dec; 54(1406):103-4. PubMed ID: 23282792
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe left atrial enlargement due to carfilzomib use in multiple myeloma.
    Dasanu CA; Plaxe SC; Popescu IM; Gupta V; Sontz E; Codreanu I
    J Oncol Pharm Pract; 2019 Dec; 25(8):2045-2048. PubMed ID: 30636528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m
    Barley K; Sanchez L; Cho HJ; Parekh S; Madduri D; Richter J; Isola L; Goldstein T; Dhadwal A; Zarychta K; Sanchez GM; Catamero D; Verina D; Florendo E; Yum MH; La L; Gullie J; Chan E; Jagannath S; Chari A
    Am J Hematol; 2020 Feb; 95(2):E51-E54. PubMed ID: 31814152
    [No Abstract]   [Full Text] [Related]  

  • 14. Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events.
    Abe Y; Kobayashi T; Narita K; Kobayashi H; Kitadate A; Miura D; Takeuchi M; Matsue K
    Blood Adv; 2019 Jun; 3(11):1725-1728. PubMed ID: 31171510
    [No Abstract]   [Full Text] [Related]  

  • 15. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.
    Fotiou D; Roussou M; Gakiopoulou C; Psimenou E; Gavriatopoulou M; Migkou M; Kanellias N; Dialoupi I; Eleutherakis-Papaiakovou E; Giannouli S; Delavinia C; Efstathiou K; Kontogiannis S; Terpos E; Dimopoulos MA; Kastritis E
    Blood Cancer J; 2020 Nov; 10(11):109. PubMed ID: 33149167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
    Siegel DS
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
    [No Abstract]   [Full Text] [Related]  

  • 17. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naproxen-associated fatal acute renal failure in multiple myeloma.
    Shpilberg O; Douer D; Ehrenfeld M; Engelberg S; Ramot B
    Nephron; 1990; 55(4):448-9. PubMed ID: 2392205
    [No Abstract]   [Full Text] [Related]  

  • 19. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
    Chavda SJ; Pocock R; Cheesman S; Lee KM; Dowling E; Marks DJB; Kyriakou C; Lee L; Sive J; Wechalekar A; Rabin N; Yong K; Popat R
    Br J Haematol; 2020 Sep; 190(5):e312-e316. PubMed ID: 32535901
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.